Cutaneous side effects of antiosteoporosis treatments

[en] Cutaneous adverse reactions are reported for many therapeutic agents and, in general, are observed in between 0% and 8% of treated patients depending on the drug. Antiosteoporotic agents are considered to be safe in terms of cutaneous effects, however there have been a number of case reports of cutaneous adverse reactions which warrant consideration. This was the subject of a working group meeting of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis in April 2009, which focused on the impact of cutaneous adverse reactions and drug-induced hypersensitivity in the management of postmenopausal osteoporosis. This position paper was drafted following these discussions and includes a flowchart for their recognition. Cutaneous adverse reactions observed with antiosteoporotic agents were reviewed and included information from case reports, regulatory documents and pharmacovigilance. These reactions ranged from benign effects including exanthematous or maculopapular eruption (drug rash), photosensitivity and urticaria, to the severe and potentially life-threatening reactions of angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), Stevens Johnson syndrome and toxic epidermal necrolysis. A review of the available evidence demonstrates that cutaneous adverse reactions occur with all commonly used antiosteoporotic treatments. Notably, there are reports of Stevens Johnson syndrome and toxic epidermal necrolysis for bisphosphonates, and of DRESS and toxic epidermal necrolysis for strontium ranelate. These severe reactions remain very rare (<1 in 10,000 cases). In general, with proper management and early recognition, including immediate and permanent withdrawal of the culprit agent, accompanied by hospitalization, rehydration and systemic corticosteroids if necessary, the prognosis is positive. © The Author(s), 2011.

Disciplines :

General & internal medicine

Author, co-author :

Musette, P.; Department of Dermatology, Rouen University Hospital, 76038 Rouen, France

Kaufman, J.-M.; Department of Internal Medicine, Gent University Hospital, B-9000 Gent, Belgium

Rizzoli, R.; Department of Rehabilitation and Geriatrix - Service of Bone Diseases, Geneva University Hospital, 1211 Geneva 14, Switzerland

Cacoub, P.; Department of Internal Medicine, AP-HP, Hôpital Pitié Salpétrière and Université Pierre et Marie Curie, 75013 Paris, France

Brandi, M. L.; Department of Internal Medicine, University of Florence, 50139 Florence, Italy

REGINSTER, Jean-Yves ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur

Language :

English

Title :

Cutaneous side effects of antiosteoporosis treatments

Publication date :

2011

Journal title :

Therapeutic Advances in Musculoskeletal Disease

ISSN :

1759-720X

eISSN :

1759-7218

Publisher :

SAGE Publications, New York, United States - New York

Volume :

Issue :

Pages :

31-41

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 18 October 2013

Statistics

Number of views

60 (2 by ULiège)

Number of downloads

1 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Aberer W. Kranke B. (2008) Clinical manifestations and mechanisms of skin reactions after systemic drug administration. Drug Discovery Today 5: e237–e247.
Allanore L. Roujeau J.C. (2007) Clinic and pathogenesis of severe bullous skin reactions: Stevens–Johnson syndrome, toxic epidermal necrolysis. In: Ed. Pichler W.J. (ed.) Drug Hypersensitivity. Basel: Karger, pp. 267–277.
Autier P. Haentjens P. Bentin J. Baillon J.M. Grivegnee A.R. Closon M.C. et al (2000) Costs induced by hip fractures: A prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 11: 373–380.
Barrera B.A. Wilton L. Harris S. Shakir S.A. (2005) Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. Osteoporos Int 16: 1989–1998.
Belhadjali H. Slim R. Aouam K. Youssef M. Zili J. (2008) Cutaneous vasculitis induced by risedronate. Allergy 63: 1405.
Bigby M. (2001) Rates of cutaneous reactions to drugs. Arch Dermatol 137: 765–770.
Biswas P.N. Wilton L.V. Shakir S.A. (2003) Pharmacovigilance study of alendronate in England. Osteoporos Int 14: 507–514.
Bliuc D. Nguyen N.D. Milch V.E. Nguyen T.V. Eisman J.A. Center J.R. (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301: 513–521.
Boada A. Carrascosa J.M. Leal L. Ferrandiz C. (2009) Generalized cutaneous drug eruption due to strontium ranelate. J Eur Acad Dermatol Venereol 23: 321–322.
Bocquet H. Bagot M. Roujeau J.C. (1996) Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 15: 250–257.
Borchers A.T. Lee J.L. Naguwa S.M. Cheema G.S. Gershwin M.E. (2008) Stevens–Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 7: 598–605.
Brinkmeier T. Kugler K. Lepoittevin J.P. Frosch P.J. (2007) Adverse cutaneous drug reaction to alendronate. Contact Dermatitis 57: 123–125.
Burnett-Bowie S.A. (2008) Is twice-yearly denosu-mab beneficial in postmenopausal women with osteo-penia but no history of fracture? Nat Clin Pract Endocrinol Metab 4: 660–661.
Center J.R. Nguyen T.V. Schneider D. Sambrook P.N. Eisman J.A. (1999) Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 353: 878–882.
Chrischilles E. Shireman T. Wallace R. (1994) Costs and health effects of osteoporotic fractures. Bone 15: 377–386.
Chung W.H. Hung S.I. Hong H.S. Hsih M.S. Yang L.C. Ho H.C. et al (2004) Medical genetics: A marker for Stevens–Johnson syndrome. Nature 428: 486.
Cooper C. Atkinson E.J. Jacobsen S.J. O'Fallon W.M. Melton L.J. 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137: 1001–1005.
Edwards I.R. Aronson J.K. (2000) Adverse drug reactions: Definitions, diagnosis, and management. Lancet 356: 1255–1259.
Eshki M. Allanore L. Musette P. Milpied B. Grange A. Guillaume J.C. et al (2009) Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: A cause of unpredictable multiorgan failure. Arch Dermatol 145: 67–72.
EMA (2007 a) Ibandronate. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (accessed 11 February 2009).
EMA (2007 b) Parathyroid Hormone. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (accessed 11 February 2009).
EMA (2008 a) Alendronate. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (accessed 11 February 2009).
EMA (2008 b) Zoledronic Acid. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (accessed 11 February 2009).
EMA (2008 c) Strontium Ranelate. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (accessed 11 February 2009).
EMA (2008 d) Raloxifene. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (Accessed 11 February 2009).
EMA (2008 e) Teriparatide. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu (Accessed 11 February 2009).
Faye O. Roujeau J.C. (2005) Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): Clinical experience to date. Drugs 65: 2085–2090.
FDA (2002) Risedronate. Description. US Food and Drug Administration. Available at: http://www.fda.gov (accessed 11 February 2009).
FDA (2009) Pharmapendium. US Food and Drug Administration. Available at: www.pharmapendium.com (accessed 23 February 2009).
Ghislain P.D. Roujeau J.C. (2002) Treatment of severe drug reactions: Stevens–Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 8: 5.
Gomes E.R. Demoly P. (2005) Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 5: 309–316.
Grosso A. Douglas I. Hingorani A. MacAllister R. Smeeth L. (2008) Post-marketing assessment of the safety of strontium ranelate: A novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 66: 689–694.
Groves C. (2008) Interstitial granulomatous reaction to strontium ranelate. Arch Dermatol 144: 268–269.
High W.A. Cohen J.B. Wetherington W. Cockerell C.J. (2003) Superficial gyrate erythema as a cutaneous reaction to alendronate for osteoporosis. J Am Acad Dermatol 48: 945–946.
Hung S.I. Chung W.H. Liou L.B. Chu C.C. Lin M.J. Huang H.P. et al (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102: 4134–4139.
Hunziker T. Kunzi U.P. Braunschweig S. Zehnder D. Hoigne R. (1997) Comprehensive hospital drug monitoring (CHDM): Adverse skin reactions, a 20-year survey. Allergy 52: 388–393.
Jonville-Bera A.P. Crickx B. Aaron L. Hartingh I. Autret-Leca E. (2009) Strontium ranelate-induced DRESS syndrome: First two case reports. Allergy 64: 658–659.
Kimura M. Kawada A. Murayama Y. Murayama M. (2003) Drug eruption due to alendronate sodium hydrate. Contact Dermatitis 48: 116.
Kontoleon P. Ilias I. Stavropoulos P.G. Papapetrou P.D. (2000) Urticaria after administration of alendronate. Ada Derm Venereol 80: 398.
Layton D. Clarke A. Wilton L.V. Shakir S.A. (2005) Safety profile of raloxifene as used in general practice in England: Results of a prescription-event monitoring study. Osteoporos Int 16: 490–500.
Lazarov A. Moss K. Plosk N. Cordoba M. Baitelman L. (2002) Alendronate-induced lichen planus. Isr Med Assoc J 4: 389–390.
Lee H.Y. Lie D. Lim K.S. Thirumoorthy T. Pang S.M. (2009) Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis. Osteoporos Int 20: 161–162.
Mallal S. Phillips E. Carosi G. Molina J.M. Workman C. Tomazic J. et al (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358: 568–579.
McClung M.R. Lewiecki E.M. Cohen S.B. Bolognese M.A. Woodson G.C. Moffett A.H. et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821–831.
Mockenhaupt M. (2007) Epidemiology and causes of severe cutaneous adverse reactions to drugs, In: Ed. Pichler W.J. (ed.). Drug Hypersensitivity, Karger: Basel, pp. 18–31.
Mockenhaupt M. Viboud C. Dunant A. Naldi L. Halevy S. Bouwes-Bavinck J.N. et al (2008) Stevens–Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128: 35–44.
Morison W.L. (2004) Clinical practice. Photosensitivity. N Engl J Med 350: 1111–1117.
Pernicova I. Middleton E.T. Aye M. (2008) Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos Int 19: 1811–1812.
Rizos E.C. Milionis H.J. Elisaf M.S. (2006) Fever with rash following zolendronic acid administration. Clin Exp Rheumatol 24: 455.
Roujeau J.C. (2005) Clinical heterogeneity of drug hypersensitivity. Toxicology 209: 123–129.
Schnyder B. Pichler W.J. (2009) Mechanisms of drug-induced allergy. Mayo Clin Proc 84: 268–272.
Shiohara T. Inaoka M. Kano Y. (2006) Drug-induced hypersensitivity syndrome (DIHS): A reaction induced by a complex interplay among herpes viruses and antiviral and antidrug immune responses. Allergol Int 55: 1–8.
Shiohara T. Takahashi R. Kano Y. (2007) Drug-induced hypersensitivity syndrome and viral reactivation, In: Ed. Pichler W.J. (ed.). Drug Hypersensitivity, Karger: Basel, pp. 251–266.
Svensson C.K. Cowen E.W. Gaspari A.A. (2001) Cutaneous drug reactions. Pharmacol Rev 53: 357–379.
Valeyrie-Allanore L. Sassolas B. Roujeau J.C. (2007) Drug-induced skin, nail and hair disorders. Drug Saf 30: 1011–1030.
Viard I. Wehrli P. Bullani R. Schneider P. Holler N. Salomon D. et al (1998) Inhibition of toxic epidermal necrolysis by blockade of CD 95 with human intravenous immunoglobulin. Science 282: 490–493.
Vidal L. (2009) Le Dictionnaire, 85th edn, Issy-les-Moulineaux, France: Vidal.
Wolf R. Orion E. Marcos B. Matz H. (2005) Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 23: 171–181.